303 related articles for article (PubMed ID: 25572820)
1. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis.
Puig L; Ruiz-Salas V
Dermatology; 2015; 230(1):46-54. PubMed ID: 25572820
[TBL] [Abstract][Full Text] [Related]
2. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
3. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
[TBL] [Abstract][Full Text] [Related]
5. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
6. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.
Clemmensen A; Spon M; Skov L; Zachariae C; Gniadecki R
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1037-40. PubMed ID: 21108668
[TBL] [Abstract][Full Text] [Related]
7. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
[TBL] [Abstract][Full Text] [Related]
9. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
11. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
12. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
14. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
[TBL] [Abstract][Full Text] [Related]
16. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
17. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
[TBL] [Abstract][Full Text] [Related]
18. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
[TBL] [Abstract][Full Text] [Related]
20. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]